This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Series

David Humphreys, PhD
Director, Antibody Biology at UCB-New Medicines


David Humphreys graduated with a degree in molecular biology from the University of Durham (UK) in 1992 before completing a PhD at the University of Birmingham (UK) in 1995. His PhD investigated augmented heterologous protein expression in the E. coli periplasm, using protein disulphide isomerase as a chaperone.

David joined UCB (formerly Celltech) in 1995 where he first studied aspects of the engineering of antibody constructs and their expression in E. coli. Research interests have included; Fab and antibody engineering, Bispecific antibodies, FcR biology, E. coli and CHO engineering, protein secretion and folding and PEGylation strategies. David leads the New Modality Therapeutics team working on various aspects of drug discovery and engineering. David was leader of a project identifying therapeutic Mabs to treat Clostridium difficile and a project to block FcgR’s. His work has resulted in multiple peer reviewed publications, reviews and granted patents.